# OPUS GENETICS INC.: Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA.

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | OPUS GENETICS INC. |
| Location | RALEIGH, NC |
| Project | Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA. |
| Project number | 1R44EY038149-01A1 |
| Mechanism | R44 |
| Institute | National Eye Institute |
| Award | $1,012,469 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-15 to 2028-05-31 |
| UEI | YD2GB4S983V9 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11409872). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.